|Proteon Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference|
WALTHAM, MA., February 4, 2013 — Proteon Therapeutics, Inc., a private biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, today announced that Timothy Noyes, President and Chief Executive Officer, will be presenting a corporate overview at the 15th Annual BIO CEO & Investor Conference in New York. Mr. Noyes’ presentation is scheduled to begin at 9:00 a.m. EST on Monday, February 11, 2013.
The presentation follows Proteon’s recent announcement of its successful Phase 2 clinical trial of PRT-201 in chronic kidney disease patients undergoing surgical placement of an arteriovenous fistula (AVF) in preparation for hemodialysis. The Phase 2 results demonstrated that treatment with PRT-201 prolonged primary unassisted patency and improved the rate of AVF maturation. Additionally, PRT-201 was well tolerated at the doses tested.
A replay of the presentation will be archived on Proteon’s website http://www.proteontherapeutics.com.
PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve outcomes in patients suffering from vascular disease. Elastase has been shown in certain preclinical settings to reduce neointimal hyperplasia formation and to cause dilation of segments of arteries and veins. These effects may decrease stenosis and prolong vessel patency. Improved patency may lead to fewer corrective surgical procedures, fewer hospitalizations, lower costs and less suffering for patients. PRT-201 has received fast track and orphan drug designations from the FDA for the indication of improving AVF and AVG surgical outcomes.
About Proteon Therapeutics
Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, MA., and has research facilities in Kansas City, MO. For additional information, please visit www.proteontherapeutics.com.
President and CEO